Online citations, reference lists, and bibliographies.
← Back to Search

Anxiolytics, Sedatives, And Miscellaneous Drugs

J. Werry, M. Aman
Published 1999 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This chapter contains discussions of anxiolytics and sedatives and several miscellaneous drugs that do not fit naturally into the remaining drug chapters. Included here are reviews of central nervous system (CNS) depressants (such as the benzodiazepines), antihistamines and anticholinergics, and atypical anxiolytics. Under the rubric of “miscellaneous drugs,” we have included Clonidine and guanfacine, melatonin, hypericin, tryptophan and 5-hydroxytryptophan, fenfluramine, the s-blockers, and the opiate antagonists.
This paper references
10.1056/NEJM199708283370911
Further cases of valvular heart disease associated with fenfluramine-phentermine.
D. Graham (1997)
10.1097/00004583-199401000-00021
Safety of clonidine and nortriptyline.
N. Chapman (1994)
10.1111/J.1469-7610.1985.TB01643.X
A double-blind drug trial of treatment in young children with waking problems.
N. Richman (1985)
10.1111/j.1526-4610.1991.hed3105333.x
Propranolol in the Management of Recurrent Migraine: A Meta‐analytic Review
K. Holroyd (1991)
10.1111/j.1469-8749.1994.tb11818.x
THE TREATMENT OF SLEEP DISORDERS WITH MELATONIN
J. E. Jan (1994)
10.1097/00004583-199403000-00014
Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD.
R. Steingard (1994)
Opioid antagonist effects on self-injury in adults with mental retardation: response form and location as determinants of medication effects.
T. Thompson (1994)
10.1007/BF02211954
Clinical effects of fenfluramine on children with autism: A review of the research
Gabrielle Verglas (1988)
10.1097/00004583-199403000-00011
Clonazepam in childhood anxiety disorders.
F. Graae (1994)
10.1097/00004714-198904000-00009
Clinical effect of buspirone in autistic children.
G. Realmuto (1989)
Goodman & Gilman's The Pharmacological Basis of Therapeutics
M. Leider (1985)
10.1097/00004583-199508000-00007
Current knowledge of medications for the treatment of childhood anxiety disorders.
A. J. Allen (1995)
10.1176/AJP.151.11.1704
American Psychiatric Press Review of Psychiatry, vol. 12
Troy L. Thompson (1994)
10.1097/00004850-199100640-00007
Drug interactions in psychiatry
D. Ciraulo (1989)
10.2165/00003088-198814050-00002
Clinical Pharmacokinetics of Clonidine
D.T. Lowenthal (1988)
10.1089/CAP.1995.5.157
Combining Methylphenidate and Clonidine: Pharmacologic Questions and News Reports about Sudden Death
C. Popper (1995)
10.1016/S0002-7138(09)62331-1
The nuclear family, suburban neurosis, and iatrogenesis in Auckland mothers of young children.
J. Werry (1983)
10.1089/CAP.1994.4.101
Nadolol for Self-Injury, Overactivity, Inattention, and Aggression in a Child with Pervasive Developmental Disorder
D. Connor (1994)
10.1016/0531-5565(94)00045-5
The pineal gland and melatonin in relation to aging: A summary of the theories and of the data
R. Reiter (1995)
10.1037//0022-006X.63.2.327
Enhancing the effectiveness of relaxation-thermal biofeedback training with propranolol hydrochloride.
K. Holroyd (1995)
10.2165/00003495-197510040-00001
Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.
R. Pinder (1975)
10.1089/CAP.1994.4.129
Buspirone Treatment of Traumatic Brain Injury in a Child Who Is Highly Sensitive to Adverse Effects of Psychotropic Medications
M. Mandoki (1994)
10.1089/cap.1990.1.87
Clonidine in child and adolescent psychiatry.
R. D. Hunt (1990)
10.1097/00004583-199201000-00017
Child panic revisited.
D. Klein (1992)
10.1097/00004583-199107000-00002
Overanxious disorder: a review of its taxonomic properties.
J. Werry (1991)
10.1089/CAP.1995.5.215
Guanfacine for Treatment of Attention-Deficit Hyperactivity Disorder in Boys
J. Horrigan (1995)
10.1097/00004583-199305000-00013
Treatment of aggressive children with clonidine: results of an open pilot study.
J. Kemph (1993)
10.1097/00004583-199606000-00009
Melatonin for sleep problems.
K. Masters (1996)
10.1056/NEJM199708283370912
Valvular heart disease associated with dexfenfluramine.
L. B. Cannistra (1997)
10.1097/00004583-199211000-00017
Case Study: Buspirone-Associated Mental Status Changes
P. Soni (1992)
10.1016/S0022-3476(05)81621-X
Clonidine poisoning in young children.
J. Wiley (1990)
10.1097/00004583-199510000-00009
Buspirone in ADHD with ODD.
M. Gross (1995)
10.1007/978-1-4613-8774-9_7
Novel Psychoactive Agents in the Treatment of Developmental Disorders
Mae S. Sokol (1988)
10.1016/0165-1781(95)02749-M
Placebo-controlled acute dosage naltrexone study in young autistic children
S. Willemsen-Swinkels (1995)
10.1097/00004583-199401000-00022
SAFETY OF CLONIDINE AND NORTRIPTYLINE
T. Wilens (1994)
10.1111/j.1365-2265.1995.tb01869.x
Role of melatonin in health and disease
S. Webb (1995)
Rationale for the administration of opiate antagonists in treating infantile autism.
S. Deutsch (1986)
10.1097/00004583-199402000-00016
Treatment with propranolol of severe self-injurious behavior in a blind, deaf, retarded adolescent.
C. Lang (1994)
10.1001/ARCHPSYC.1995.03950210060011
Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies.
S. Willemsen-Swinkels (1995)
10.1016/S0002-7138(09)60065-0
Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial.
R. D. Hunt (1985)
10.1111/J.1469-7610.1985.TB01642.X
Behavioural methods in the treatment of sleep disorders--a pilot study.
N. Richman (1985)
10.1089/cap.1991.1.361
Beta blockers in mental retardation and developmental disorders.
L. E. Arnold (1991)
10.1097/00004583-199107000-00001
Anxiety disorders of childhood and adolescence: a critical review.
G. Bernstein (1991)
10.1080/07263869100034401
Pharmacotherapy in the developmental disabilites: New developments
M. Aman (1991)
10.1097/00004583-199502000-00018
Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.
B. K. Kolmen (1995)
10.1016/S0033-3182(87)72521-3
Use of propranolol to decrease aggressive outbursts in younger patients. Open study reveals potentially favorable outcome.
S. Kuperman (1987)
Special considerations in the poisoned pediatric patient.
F. Henretig (1994)
Fenfluramine: evidence for a neurotoxic action on midbrain and a long-term depletion of serotonin.
Harvey Ja (1975)
10.1089/cap.1990.1.57
Anxiolytics for children and adolescents: traditional and new drugs.
B. Coffey (1990)
10.1089/CAP.1990.1.237
The Opiate Hypothesis in Autism and Self-Injury
C. Sandman (1990)
10.1097/00004583-198201000-00007
Methylphenidate and diazepam in severe reading retardation.
M. Aman (1982)
10.1016/S0193-953X(18)30257-0
The pharmacotherapy of anxiety disorders in children and adolescents.
S. Kutcher (1992)
10.1089/CAP.1995.5.301
Clonidine in the Treatment of ADHD: Questions about Safety and Efficacy
J. Swanson (1995)
10.1089/CAP.1995.5.155
Combining Methylphenidate and Clonidine: The Role of Post-Marketing Surveillance
R. R. Fenichel (1995)
10.1136/bmj.313.7052.253
St John's wort for depression—an overview and meta-analysis of randomised clinical trials
K. Linde (1996)
10.1007/978-1-4615-5877-4
The Practitioner’s Guide to Psychoactive Drugs
FOURTH EDITION (1997)
10.1111/J.1469-7610.1988.TB00684.X
Fenfluramine treatment of autism.
M. Campbell (1988)
10.1016/0165-0327(87)90017-6
Beta-blockers in anxiety disorders.
P. E. Hayes (1987)
10.1136/bmj.313.7052.241
St John's wort as an antidepressant
P. D. De Smet (1996)
10.1016/S0270-3092(83)80014-9
Naloxone attenuates self-abusive behavior in developmentally disabled clients.
C. Sandman (1983)
Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: clinical effects.
M. Aman (1997)
10.1097/00004583-198907000-00014
Review of fenfluramine in the treatment of the developmental disabilities.
M. Aman (1989)
Psychopharmacologic treatment of anxiety disorders in adolescents and children.
C. Popper (1993)
10.1097/00004583-199311000-00024
Naltrexone in autistic children: behavioral symptoms and attentional learning.
M. Campbell (1993)
10.3109/10401239309148981
Efficacy of psychotropic drugs for reducing self-injurious behavior in the developmental disabilities.
M. Aman (1993)
10.1097/00004583-199501000-00013
An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder.
R. D. Hunt (1995)
10.1001/ARCHPSYC.1989.01810030011002
Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings.
M. Donnelly (1989)
The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine.
H. Singer (1995)
10.1089/CAP.1994.4.211
Clonidine Extended-Release Capsules as an Alternative to Oral Tablets and Transdermal Patches
H. Horacek (1994)
10.1097/00004583-198903000-00009
Naltrexone in autistic children: an acute open dose range tolerance trial.
M. Campbell (1989)
10.1016/S0193-953X(18)30263-6
The pharmacologic treatment of sleep disorders.
R. Dahl (1992)
10.1097/00007611-199407000-00004
Clonidine Therapy for Comorbid Attention Deficit Hyperactivity Disorder and Conduct Disorder: Preliminary Findings in a Children's Inpatient Unit
T. J. Schvehla (1994)
10.1177/106002808902300605
Cardiac Dysrhythmia with the Use of Clonidine in Explosive Disorder
P. Dawson (1989)
10.1016/0163-8343(95)00062-V
Treatment of delayed sleep phase syndrome.
Q. Regestein (1995)
10.1177/153321019700300312
Klaus Linde, Gilbert Ramirez, Cynthia D. Mulrow, Andrej Pauls, Wolfgang Weidenhammer, and Dieter Melchart. (1996). St. John's wort for depression—An overview and meta-analysis of randomized clinical trials. British Medical Journal, 313, 3 August 1996, 253-8
M. Hazzard (1997)
10.1016/S0193-953X(18)30258-2
The pharmacologic treatment of conduct disorders and rage outbursts.
M. Campbell (1992)
10.1002/ANA.410290318
Correction of non–24‐hour sleep/wake cycle by melatonin in a blind retarded boy
L. Palm (1991)
Benzodiazepines in Clinical Practice
R. Shader (1974)
A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.
M. Fankhauser (1992)
10.1016/S0193-953X(18)30260-0
Pharmacotherapy of Tourette's syndrome and associated disorders.
D. Cohen (1992)
10.1093/MILMED/151.1.386
Goodman and Gilman's the Pharmacological Basis of Therapeutics
W. Stigelman (1986)
10.7326/0003-4819-72-6-971_2
Manic-Depressive Illness
F. Goodwin (1990)
10.1037/1064-1297.1.1-4.242
Naltrexone reduces self-injury and improves learning.
C. Sandman (1993)
10.1056/NEJM199708283370901
Valvular heart disease associated with fenfluramine-phentermine.
H. Connolly (1997)
10.1089/CAP.1994.4.159
Buspirone Therapy of Mixed Anxiety Disorders in Childhood and Adolescence: A Pilot Study
J. G. Simeon (1994)
10.1097/00004583-199307000-00022
Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects.
M. Aman (1993)
10.1111/J.1469-7610.1992.TB00886.X
Annotation: Sleep and its Disorders in Children
J. Horne (1992)
10.1097/00004583-199501000-00011
Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder.
D. Geller (1995)
10.1016/S0022-3476(05)80377-4
The pineal gland in human beings: relevance to pediatrics.
A. Cavallo (1993)
10.1056/NEJM198207153070307
Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys.
E. Geller (1982)
10.1097/00004583-199605000-00014
Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases.
J. Prince (1996)
10.1001/ARCHPEDI.1988.02150110122036
Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study.
R. Famularo (1988)
10.1007/BF01495056
Brain opioids and autism: An updated analysis of possible linkages
Tony L. Sahley (1987)
10.1097/00004583-199501000-00021
Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology.
T. Wilens (1995)
10.1089/cap.1993.3.157
Cardiovascular and other physical effects of acute administration of naltrexone in autistic children.
B. Herman (1993)
10.1097/00004714-199210000-00005
Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder
C. Jaselskis (1992)
10.1097/00004583-199411000-00023
ECG and clonidine.
K. Chandran (1994)
10.1097/00004583-198901000-00001
Behavior therapy with children and adolescents: a twenty-year overview.
J. Werry (1989)
10.1097/00004583-199403000-00018
Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder.
T. Wilens (1994)
10.1177/154596839500900106
Treatment of Viral Encephalitis Organic Personality Disorder and Autistic Features with Propranolol: A Case Report
J. G. Schmidt (1995)
10.1089/cap.1993.3.127
Case report: development of precocious puberty in two children treated with clonidine for aggressive behavior.
G. M. Levin (1993)
10.1176/AJP.152.7.1087
Lack of effect of clonidine on stuttering in children.
M. Althaus (1995)
10.1097/00004583-199201000-00006
Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders.
J. G. Simeon (1992)
10.1097/00004583-199409000-00011
Buspirone use in an adolescent with social phobia and mixed personality disorder (cluster A type).
K. J. Zwier (1994)
10.1002/1098-108X(199411)16:3<257::AID-EAT2260160306>3.0.CO;2-3
Melatonin disturbances in anorexia nervosa and bulimia nervosa.
S. Kennedy (1994)
10.1136/adc.65.1.112
Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial.
M. Selikowitz (1990)
Sleep and its disorders in children
C. Guilleminault (1987)



This paper is referenced by
AN EXAMINATION OF PSYCHOTROPIC MEDICATION PRESCRIPTION PRACTICES AMONG INDIVIDUALS WITH MENTAL RETARDATION
A. Thesis (2005)
10.1016/S1056-4993(18)30138-X
Pharmacologic treatment of anxiety disorders in children and adolescents.
J. Velosa (2000)
10.1023/A:1005559725475
Pharmacotherapy for Hyperactivity in Children with Autism and Other Pervasive Developmental Disorders
M. Aman (2000)
An examination of psychotropic medication prescription practices among individuals with mental retardation
A. N. Singh (2005)
10.1037/0735-7028.33.2.135
Pediatric psychopharmacology: A review of new developments and recent research
Ronald T. Brown (2002)
10.1016/S0074-7750(03)01005-X
Prevalence and Correlates of Psychotropic Medication Use among Adults with Developmental Disabilities: 1970–2000
Maria G. Valdovinos (2003)
10.1016/j.chc.2008.06.009
Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.
M. Aman (2008)
10.3928/0090-4481-20010301-08
Medication for the management of anxiety disorders in children and adolescents.
T. Williams (2001)
10.1007/978-1-4615-5905-4_12
Self-Injurious Behavior and Stereotypies
J. Rojahn (1998)
10.1097/00008480-200310000-00007
Pharmacologic management of anxiety disorders in children and adolescents
T. Williams (2003)
10.1002/(SICI)1098-2779(1999)5:4<335::AID-MRDD11>3.0.CO;2-2
Nutritional, dietary, and hormonal treatments for individuals with mental retardation and developmental disabilities
C. Ellis (1999)
10.1007/978-1-4615-4881-2_26
Disruptive behavior disorders in children with mental retardation.
B. Benson (1999)
10.1016/J.RIDD.2005.03.003
Neurochemical correlates of autistic disorder: a review of the literature.
K. S. Lam (2006)
10.1002/9780470939406.CH8
8. Autism Spectrum Disorders
Geraldine Dawson and (2015)
10.1097/00004583-199701000-00032
Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. American Academy of Child and Adolescent Psychiatry.
J. McClellan (1997)
10.1097/00004583-200209000-00002
Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
R. Snyder (2002)
Semantic Scholar Logo Some data provided by SemanticScholar